Pharmacovigilance and public health ethics

Pharmaceutical Medicine

Volumn 27, Issue 3, 2013, Pages 157-164

  Callréus, Torbjörn ^a  

^a Danish Health and Medicines Authority   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOETHICS; DRUG SURVEILLANCE PROGRAM; HUMAN; MASS SCREENING; MORALITY; PATERNALISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

EID: 84878539946     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-013-0016-4     Document Type: Review

References (52)

1. Dawson A, Verweij M. Public Health Ethics: a manifesto. Public Health Ethics. 2008;1(1):1-2.
2. Buchanan DR, Miller FG. A public health perspective on research ethics. J Med Ethics. 2006;32(12):729-33.
3. World Health Organisation. The importance of pharmacovigilance: safety monitoring of medicinal products (online). http://apps.who.int/medicinedocs/pdf/ s4893e/s4893e.pdf. Accessed 22 Aug 2012.
4. Waller P. Risk management planning: time to deliver. Pharmacoepidemiol Drug Saf. 2006;15(12):850-1.
5. Edwards IR. Prevention and pharmacovigilance: what should we do, what can we do? Drug Saf. 2012;35(2):87-90.
6. Winslow CE. The untilled fields of public health. Science. 1920;51(1306):23-33.
7. Coughlin SS. Ethical issues in epidemiologic research and public health practice. Emerg Themes Epidemiol. 2006;3:16.
8. Rothstein MA. Rethinking the meaning of public health. J Law Med Ethics. 2002;30(2):144-9.
9. Verweij M, Dawson A. The meaning of "public" in "public health". In: Dawson A, Verweij M, editors. Ethics, prevention and public health. Oxford: Clarendon Press; 2007. p. 13-29.
10. Childress JF, Faden RR, Gaare RD, Gostin LO, Kahn J, Bonnie RJ, et al. Public health ethics: mapping the terrain. J Law Med Ethics. 2002;30(2):170-8.
11. Buchanan DR. Autonomy, paternalism, and justice: ethical priorities in public health. Am J Public Health. 2008;98(1):15-21.
12. Freeman M, editor. The ethics of public health, vols. I & II. London: Ashgate Publishing Limited; 2010.
13. Dawson A, Verweij M. Introduction: ethics, prevention, and public health. In: Dawson A, Verweij M, editors. Ethics, prevention and public health. Oxford: Clarendon Press; 2007. p. 1-12.
14. Reverby SM. Listening to narratives from the Tuskegee syphilis study. Lancet. 2011;377(9778):1646-7.
15. Bristol N. US reviews human trial participant protections. Lancet. 2010;376(9757):1975-6.
16. Carroll R. Guatemala victims of US syphilis study still haunted by the "devils experiment". Guard Wkl. 2011;17:9.
17. Coleman CH, Bouesseau MC, Reis A. The contribution of ethics to public health. Bull World Health Organ. 2008;86(8):578-A.
18. Verweij M, Dawson A. Public health research ethics: a research agenda. Public Health Ethics. 2009;2(1):1-6.
19. Merriam-Webster Dictionary. Definition of ethics (online). http://www.merriam-webster.com/dictionary/ethics. Accessed 22 Aug 2012.
20. Kass NE. Public health ethics: from foundations and frameworks to justice and global public health. J Law Med Ethics. 2004;32(2):232-42, 190.
21. Bayer R, Fairchild AL. The genesis of public health ethics. Bioethics. 2004;18(6):473-92.
22. Gostin L. Ethical principles for the conduct of human subject research: population-based research and ethics. Law Med Health Care. 1991;19(3-4):191-201.
23. Beauchamp T, Childress JF. Principles of biomedical ethics. 5th ed. Oxford: Oxford University Press; 2001.
24. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects (online). http://www.wma.net/en/ 30publications/10policies/b3/index.html.pdf. Accessed 22 Aug 2012.
25. Krebs J. The importance of public-health ethics. Bull World Health Organ. 2008;86(8):579.
26. Callreus T. Perceptions of vaccine safety in a global context. Acta Paediatr. 2010;99(2):166-71.
27. Weinreb SL. For the herd's sake, vaccinate. Int Herald Tribune. 2011;29:8.
28. Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. J Glob Infect Dis. 2011;3(2):143-50.
29. Brock DW. Broadening the bioethics agenda. Kennedy Inst Ethics J. 2000;10(1):21-38.
30. Petrini C. Theoretical models and operational frameworks in public health ethics. Int J Environ Res Public Health. 2010;7(1):189-202.
31. Dawson A. Editorial: political philosophy and public health ethics. Public Health Ethics. 2009;2(2):121-2.
32. Richter ED, Laster R. The precautionary principle, epidemiology and the ethics of delay. Int J Occup Med Environ Health. 2004;17(1):9-16.
33. Callreus T. The precautionary principle and pharmaceutical risk management. Drug Saf. 2005;28(6):465-71.
34. Duster T. Explaining differential trust of DNA forensic technology: grounded assessment or inexplicable paranoia? J Law Med Ethics. 2006;34(2):293-300.
35. Harris RL, Seid M, editors. Globalization and health. Boston: Brill; 2004.
36. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366-71.
37. Institute of Medicine. Ethical and scientific issues in studying the safety of approved drugs (online). http://www.nap.edu/catalog.php?record-id= 13219. Accessed 22 Aug 2012.
38. Ronaldson KJ. Maintaining and enhancing the value of spontaneous reporting programmes. Pharm Med. 2011;25(2):83-6.
39. CIOMS. International ethical guidelines for epidemiological studies. 1 ed. Geneva: CIOMS; 2009.
40. International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200-8.
41. Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426-37.
42. Faigen N. US FDA halts new enrolment in GSK's TIDE trial. SCRIP Intell. 2010;3507:1.
43. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816-23.
44. Edwards IR. Conflicts of interest in medicines safety and regulation: how much conflict and how much interest should we allow? Drug Saf. 2011;34(8):617-21.
45. Horton R, Das P. The vaccine paradox. Lancet. 2011;378(9788):296-8.
46. Waller P. Getting to grips with the new European Union pharmacovigilance legislation. Pharmacoepidemiol Drug Saf. 2011;20(5):544-9.
47. Bouder F. Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes (online). http://www.ema.europa.eu/docs/en-GB/document-library/Report/2011/05/WC500106865. pdf. Accessed 22 Aug 2012.
48. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-68.
49. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):18-22.
50. Mello MM, Goodman SN, Faden RR. Ethical considerations in studying drug safety-the Institute of Medicine report. N Engl J Med. 2012;367(10):959-64.
51. CIOMS. Points to consider regarding differences between vaccines and drugs in signal detection. In: Practical aspects of signal detection in pharmacovigilance. 1 ed. Geneva: CIOMS; 2010. p. 139-43.
52. Cohen D. Rosiglitazone: what went wrong? BMJ. 2010;341:c4848.